Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Surgery, Journal, Source Type: news
More News: Cancer & Oncology | Dermatology | Immunotherapy | Melanoma | Neoadjuvant Therapy | Skin | Skin Cancer | Study